Castle Biosciences (CSTL) Depreciation and Depletion (2018 - 2026)

Castle Biosciences (CSTL) has 9 years of Depreciation and Depletion data on file, last reported at $1.7 million in Q1 2026.

• Quarterly Depreciation and Depletion rose 18.35% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 million (up 18.33% YoY) and the FY2025 annual result came in at $5.9 million, up 21.3% from the prior year.
• Depreciation and Depletion grew to $1.7 million in Q1 2026 per CSTL's latest filing, from $1.5 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $1.7 million in Q1 2026, with the low at $503000.0 in Q1 2022.
• Average Depreciation and Depletion over 5 years is $1.1 million, with a median of $1.1 million recorded in 2024.
• Year-over-year, Depreciation and Depletion soared 115.88% in 2022 and rose 5.11% in 2025.
• Castle Biosciences' Depreciation and Depletion stood at $627000.0 in 2022, then surged by 51.99% to $953000.0 in 2023, then soared by 49.84% to $1.4 million in 2024, then gained by 5.11% to $1.5 million in 2025, then increased by 13.46% to $1.7 million in 2026.
• Business Quant data shows CSTL's Depreciation and Depletion at $1.7 million in Q1 2026, $1.5 million in Q4 2025, and $1.5 million in Q3 2025.